Status: Recruiting
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
The primary objective is to compare PD-1 inhibitor combined with preoperative chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery, in terms of the overall survival time (OS) in patients with Stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal carcinoma.
Participants needed: 422
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Sun Yat-sen UniversityUpdated: Apr 30, 2026Locations: 1
Eligibility criteria
Histologic diagnosis of squamous cell thoracic esophageal carcinoma of Stage T1-... [+6]
Patients have received any prior anticancer therapy. [+13]